Errata (DOI:10.1016/S1470-2045(07)70040-2);Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis

Lancet Oncology

Volumn 8, Issue 3, 2007, Pages 212-218

  Opelz, Gerhard ^a   Daniel, Volker ^a   Naujokat, Cord ^a   Fickenscher, Helmut ^b   Döhler, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID; OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHI SQUARE TEST; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGISTER; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK REDUCTION; STANDARDIZATION;

EID: 33847136032     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70056-6     Document Type: Erratum

References (30)

1. Penn I., Hammond W., Brettschneider L., and Starzl T. Malignant lymphomas in transplantation patients. Transplant Proc 1 (1969) 106-112
2. Opelz G., and Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 222-230
3. Starzl T., Nalesnik M., Porter K., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1 (1984) 583-587
4. Hopwood P., and Crawford D. The role of EBV in post-transplant malignancies: a review. J Clin Pathol 53 (2000) 248-254
5. Opelz G., and Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342 (1993) 1514-1516
6. Funch D., Walker A., Schneider G., et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5 (2005) 2894-2900
7. Malouf M., Chhajed P., Hopkins P., et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 21 (2002) 547-554
8. McDiarmid S., Jordan S., Kim G., et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66 (1998) 1604-1611
9. Darenkov I., Marcarlli M., Basadonna G., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64 (1997) 848-852
10. Davis C., Harrison K., McVicar J., et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 9 (1995) 53-59
11. Razonable R., Brown R., Humar A., et al. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 192 (2005) 1331-1339
12. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 17 suppl 4 (2002) 31-33 35-36
13. University of Heidelberg. Collaborative Transplant Study. http://www.ctstransplant.org (accessed Dec 1, 2006)
14. Breslow N., and Day N. International Agency for Research on Cancer. The design and analysis of cohort studies. In: Heseltine E. (Ed). Statistical methods in cancer research volume II (1987), Oxford University Press, Oxford 103-115
15. Cox D. Regression models and life-tables. J R Stat Soc (B) 34 (1972) 187-220
16. Faller D., Mentzer S., and Perrine S. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 13 (2001) 360-367
17. Babcock G., Decker L., Freeman R., and Thorley-Lawson D. Epstein-Barr virus-infected memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190 (1999) 567-576
18. Qu L., Green M., Webber S., et al. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 182 (2000) 1013-1021
19. Abedi M., Linde A., Christensson B., et al. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. Int J Cancer 71 (1997) 624-629
20. Abedi M., Christensson B., Al-Masud S., et al. Gamma-globulin modulates growth of EBV-derived B-cell tumors in SCID mice reconstituted with human lymphocytes. Int J Cancer 55 (1993) 824-829
21. Nadal D., Guzman J., Frolich S., and Braun D. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation. Exp Hematol 25 (1997) 223-231
22. Haque T., Johannessen I., Dombagoda D., et al. A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J Infect Dis 194 (2006) 584-587
23. Cen H., Williams P., McWilliams H., et al. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 81 (1993) 1393-1403
24. Riddler S., Breinig M., and McKnight J. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84 (1994) 972-984
25. Green M., Reyes M., Reyes J., Webber S., and Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 3 (2001) 97-103
26. Manez R., Breing M., Linden P., et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 176 (1997) 1462-1467
27. Mattila P., Aalto S., Heikkila L., et al. Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 15 (2001) 337-342
28. Paraskevas S., Coad J., Gruessner A., et al. Posttransplant lymphoproliferative disorder in pancreas transplantation: a single-center experience. Transplantation 80 (2005) 613-622
29. Thurmann P., Sonneburg C., Valentova K., et al. Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. Eur J Clin Pharmacol 57 (2001) 235-241
30. Ghobrial I., Habermann T., Macon W., et al. Difference between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases?. Transplantation 79 (2005) 244-247